OncoBriefs: Myeloma Studies Presented at ASCO

CHICAGO (MedPage Today) -- A four-drug regimen for relapsed/refractory multiple myeloma led to objective responses in half of the patients in a preliminary clinical evaluation.
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news

Related Links:

In this study, we used large-scale electronic health records data from multiple linked UK databases to address these evidence gaps.MethodsFor this population-based cohort study, we used linked primary care, hospital, and cancer registry data from the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox models. We fitted interactions to in...
Source: The Lancet - Category: General Medicine Source Type: research
WEDNESDAY, Aug. 21, 2019 -- Patients with a form of blood cancer known as multiple myeloma who haven't responded to other therapies might have a new weapon against the disease, researchers say. A drug called selinexor appeared to help patients with...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
We report a case of DIHS secondary to bortezomib.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Condition:   Multiple Myeloma in Relapse Intervention:   Drug: Clarithromycin Lenalidomide Dexamethasone (BiRd) Regimen Sponsor:   First Hospital of Jilin University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Immunological aging is related to the development of cancer, but factors that impact this relationship are only partially understood. Several studies demonstrated that aging correlates with increased peripheral blood T lymphocyte (PBTL) expression of p16INK4a [1,2], a molecular marker associated with cellular senescence and irreversible cell cycle arrest [3]. PBTL p16INK4a levels not only increase with chronological age, but are influenced by physiologic stress caused by smoking, chemotherapy, and physical inactivity [3].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
New England Journal of Medicine,Volume 381, Issue 8, Page 727-738, August 2019.
Source: New England Journal of Medicine - Category: Internal Medicine Authors: Source Type: research
All - oral regimen linked to higher satisfaction with treatment convenience in relapsed, refractory MM
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news
Blood Cancer Journal, Published online: 20 August 2019; doi:10.1038/s41408-019-0227-3Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
Auer rods were first described in the cytoplasm of leukemia blasts by John Auer in 1906. Auer rods are commonly seen in myeloid progenitors, and serve as a diagnostic morphological feature of acute myeloid leukemia (AML) [1]. The differential diagnosis of hematopoietic neoplasms relies on the detection of cytoplasmic inclusions resembling Auer rods. Auer rod-like inclusions have been described in multiple myeloma [2], prolymphocytic leukemia (PLL) [3], B-cell acute lymphoblastic leukemia [4], chronic lymphocytic leukemia [4], splenic lymphoma [5] and nodal marginal zone lymphoma [6], which are quite distinct from the needl...
Source: Experimental Hematology - Category: Hematology Authors: Tags: Brief Communication Source Type: research
X-linked agammaglobulinemia (XLA), caused by a mutation in the Bruton’s tyrosine kinase (BTK) gene, is rarely reported in patients with recurrent hemophagocytic lymphohistiocytosis (HLH). This mutation leads to significantly reduced numbers of circulatory B cells and serum immunoglobulins in patients. Therefore, they exhibit repetitive bacterial infections since infancy, and immunoglobulin (Ig) replacement therapy is the primary treatment. HLH is a life-threatening condition with manifestations of nonremitting fever, hepatosplenomegaly, cytopenias, coagulopathy, lipid disorder, and multiple organ failure. It is cause...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Myeloma | Primary Care | Study